// App-Quantinova.ai

4007 : A novel immunotherapy, INT230-6, is able to induce high rates of complete response in mice through a cytotoxic T-cell-dependent mechanism

Researchers

Presenter

  • Ian B. Walters

Principal Investigators

  • Anja C. Bloom

  • Lewis H. Bender

  • Masaki Terabe

  • Jay A. Berzofsky

Medical Centers

  • Intensity Therapeutics, Inc., Westport, CT

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Vinblastine

  • Cisplatin/vinblastine formulation with cell penetration enhancer

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved